<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00919607</url>
  </required_header>
  <id_info>
    <org_study_id>D1444C00007</org_study_id>
    <nct_id>NCT00919607</nct_id>
  </id_info>
  <brief_title>Evaluate the Pharmacokinetics of Quetiapine Fumarate in Chinese Schizophrenic Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the pharmacokinetics of XR quetiapine
      fumarate(300mg,600mg,and 800mg once-daily) in Chinese schizophrenic patients .
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>single dose PK parameters(300mg)</measure>
    <time_frame>Day1 to 48 hour after Day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady-state multiple doses PK parameters</measure>
    <time_frame>Day 1 to 48 hours after Day7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of AEs</measure>
    <time_frame>sign ICF to Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical significant change in Lab test</measure>
    <time_frame>baseline up to Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical significant change in vital signs</measure>
    <time_frame>baseline up to Day 9</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>quetiapine fumarate extended-release 300mg,administered once-daily Day1~5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>quetiapine fumarate extended-release 300mg/Day1,600mg/Day2~6,administered once-daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>quetiapine fumarate extended-release 300mg/Day1,600mg/Day2,800mg/Day3~7,administered once-daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>quetiapine fumarate extended-release</intervention_name>
    <description>200mg,oral,single dose</description>
    <arm_group_label>3</arm_group_label>
    <other_name>SEROQUEL XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>quetiapine fumarate extended-release</intervention_name>
    <description>300mg,oral,single dose</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>SEROQUEL XR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged 18 through 60 years inclusive

          -  Schizophrenia diagnosis

          -  Body Mass Index (BMI) 20-27 kg/m2 (inclusive)

          -  Provision of written informed consent before initiation of any study

        Exclusion Criteria:

          -  AIDS &amp; hepatitis B

          -  History of seizure disorder

          -  History of episodic,idiopathic orthostatic hypotension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tianmei Si</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Institute of Mental Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2009</study_first_submitted>
  <study_first_submitted_qc>June 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2009</study_first_posted>
  <last_update_submitted>March 25, 2010</last_update_submitted>
  <last_update_submitted_qc>March 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>MC MD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>quetiapine fumarate(SEROQUEL) extended-release(XR) China PK Study</keyword>
  <keyword>pharmacokinetics parameters</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

